Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
May 04, 2022 16:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor...
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
May 04, 2022 07:30 ET
|
Genenta Science
No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial MILAN, Italy and NEW YORK, May 04, 2022 ...
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma
May 02, 2022 16:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
Genenta Announces Nomination of Mark A. Sirgo as Chair
April 27, 2022 07:30 ET
|
Genenta Science
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta...
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors
April 20, 2022 07:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
March 09, 2022 07:46 ET
|
Genenta Science
MILAN, Italy and NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
Genenta to Participate at Upcoming Investor Conferences
February 24, 2022 07:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
Genenta Closes Its Upsized Initial Public Offering of American Depository Shares
December 17, 2021 16:15 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor...
Genenta Announces Pricing of Upsized Initial Public Offering
December 14, 2021 22:36 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
Genenta To Present Updated Phase I/II Data At Upcoming Scientific Congresses SNO AND ASH
November 16, 2021 07:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...